Picking the winners in a sea of plentySCHER, Howard I; HELLER, Glenn.Clinical cancer research. 2002, Vol 8, Num 2, pp 400-404, issn 1078-0432Article

Novel strategies and therapeutics for the treatment of prostate carcinomaMORRIS, Michael J; SCHER, Howard I.Cancer. 2000, Vol 89, Num 6, pp 1329-1348, issn 0008-543XArticle

Outcome predictions for patients with metastatic prostate cancerSMALETZ, Oren; SCHER, Howard I.Seminars in urologic oncology. 2002, Vol 20, Num 2, pp 155-163, issn 1081-0943Article

Circulating Tumor Cells as Biomarkers in Prostate Cancer : Therapeutic Advances in Prostate CancerDANILA, Daniel C; FLEISHER, Martin; SCHER, Howard I et al.Clinical cancer research (Print). 2011, Vol 17, Num 12, pp 3903-3912, issn 1078-0432, 10 p.Article

The association between measures of progression and survival in castrate-metastatic prostate cancerSCHER, Howard I; WARREN, Mary; HELLER, Glenn et al.Clinical cancer research. 2007, Vol 13, Num 5, pp 1488-1492, issn 1078-0432, 5 p.Article

Biology of progressive, castration-resistant prostate cancer : Directed therapies targeting the androgen-receptor signaling axisSCHER, Howard I; SAWYERS, Charles L.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8253-8261, issn 0732-183X, 9 p.Article

Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate CancerKNUDSEN, Karen E; SCHER, Howard I.Clinical cancer research (Print). 2009, Vol 15, Num 15, pp 4792-4798, issn 1078-0432, 7 p.Article

Prostate carcinoma: Defining therapeutic objectives and improving overall outcomesSCHER, Howard I.Cancer. 2003, Vol 97, Num 3, pp 758-771, issn 0008-543X, 14 p., SUPConference Paper

End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical PracticeSCHER, Howard I; MORRIS, Michael J; BASCH, Ethan et al.Journal of clinical oncology. 2011, Vol 29, Num 27, pp 3695-3704, issn 0732-183X, 10 p.Article

Setting the bar in phase II trials : The use of historical data for determining Go/No Go decision for definitive phase III testing. CommentaryVICKERS, Andrew J; BALLEN, Vennus; SCHER, Howard I et al.Clinical cancer research. 2007, Vol 13, Num 3, issn 1078-0432, 781-782, 972-976 [8 p.]Article

Prostate cancer clinical trial end points : RECISTing a step backwardsSCHER, Howard I; MORRIS, Michael J; KELLY, William K et al.Clinical cancer research. 2005, Vol 11, Num 14, pp 5223-5232, issn 1078-0432, 10 p.Article

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapySLOVIN, Susan F; WILTON, Andrew S; HELLER, Glenn et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8669-8673, issn 1078-0432, 5 p., 1Article

Hsp90 as a therapeutic target in prostate cancerSOLIT, David B; SCHER, Howard I; ROSEN, Neal et al.Seminars in oncology. 2003, Vol 30, Num 5, pp 709-716, issn 0093-7754, 8 p.Article

Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancerSIROTNAK, Francis M; YOHUNG SHE; FEI LEE et al.Clinical cancer research. 2002, Vol 8, Num 12, pp 3870-3876, issn 1078-0432, 7 p.Article

Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and TherapeuticsSCHER, Howard I; FULD NASSO, Shelley; RUBIN, Eric H et al.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6634-6640, issn 1078-0432, 7 p.Article

Quantifying the amount of variation in survival explained by prostate-specific antigenVERBEL, David A; HELLER, Glenn; KELLY, William K et al.Clinical cancer research. 2002, Vol 8, Num 8, pp 2576-2579, issn 1078-0432Article

Critical function for ADAM9 in mouse prostate cancerPEDUTO, Lucie; REUTER, Victor E; SHAFFER, David R et al.Cancer research (Baltimore). 2005, Vol 65, Num 20, pp 9312-9319, issn 0008-5472, 8 p.Article

Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer CenterMORRIS, Michael J; SCHER, Howard I.Critical reviews in oncology/hematology. 2003, Vol 46, pp S21-S31, issn 1040-8428, SUPConference Paper

Assessing Outcomes in Prostate Cancer Clinical Trials : A Twenty-First Century Tower of BabelGIGNAC, Gretchen A; MORRIS, Michael J; HELLER, Glenn et al.Cancer. 2008, Vol 113, Num 5, pp 966-974, issn 0008-543X, 9 p.Article

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxolSOLIT, David B; BASSO, Andrea D; OLSHEN, Adam B et al.Cancer research (Baltimore). 2003, Vol 63, Num 9, pp 2139-2144, issn 0008-5472, 6 p.Article

Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elementsSTEINECK, Gunnar; REUTER, Victor; KELLY, William K et al.Acta oncologica (Stockholm). 2002, Vol 41, Num 7-8, pp 668-674, issn 0284-186X, 7 p.Article

Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate TumorsCENTENERA, Margaret M; GILLIS, Joanna L; YEADON, Trina et al.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3562-3570, issn 1078-0432, 9 p.Article

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate CancerRATHKOPF, Dana; LIU, Glenn; FUNG, Nga Kit Eliza et al.Clinical cancer research (Print). 2011, Vol 17, Num 4, pp 880-887, issn 1078-0432, 8 p.Article

TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateDANILA, Daniel C; ANAND, Aseem; SCHER, Howard I et al.European urology. 2011, Vol 60, Num 5, pp 897-904, issn 0302-2838, 8 p.Article

Susceptibility Loci Associated with Prostate Cancer Progression and MortalityGALLAGHER, David J; VIJAI, Joseph; DUTRA-CLARKE, Ana et al.Clinical cancer research (Print). 2010, Vol 16, Num 10, pp 2819-2832, issn 1078-0432, 14 p.Article